当前位置：
X-MOL 学术
›
J. Allergy Clin. Immunol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Non-PTLD Malignancy post HSCT in patients with Primary Immunodeficiency: UK experience
Journal of Allergy and Clinical Immunology ( IF 11.4 ) Pub Date : 2018-03-07 , DOI: 10.1016/j.jaci.2018.02.038 Mohamed Najib Mohamed Unni 1 , Reem Elfeky 2 , Kanchan Rao 2 , Zohreh Nademi 1 , Robert Chiesa 2 , Persis Amrolia 2 , Roderick Skinner 1 , Olga Slater 2 , Austen Worth 2 , Terence Flood 1 , Mario Abinun 1 , Sophie Hambleton 3 , Waseem Qasim 2 , Hubert B Gaspar 2 , Andrew J Cant 1 , Andrew R Gennery 3 , Paul Veys 2 , Mary A Slatter 3
中文翻译：
原发性免疫缺陷患者 HSCT 后的非 PTLD 恶性肿瘤：英国经验
更新日期：2018-03-08
Journal of Allergy and Clinical Immunology ( IF 11.4 ) Pub Date : 2018-03-07 , DOI: 10.1016/j.jaci.2018.02.038 Mohamed Najib Mohamed Unni 1 , Reem Elfeky 2 , Kanchan Rao 2 , Zohreh Nademi 1 , Robert Chiesa 2 , Persis Amrolia 2 , Roderick Skinner 1 , Olga Slater 2 , Austen Worth 2 , Terence Flood 1 , Mario Abinun 1 , Sophie Hambleton 3 , Waseem Qasim 2 , Hubert B Gaspar 2 , Andrew J Cant 1 , Andrew R Gennery 3 , Paul Veys 2 , Mary A Slatter 3
Affiliation
Secondary malignancy post haematopoietic stem cell transplantation (HSCT) for malignant disorders is well recognized. There are very few published reports on malignancy post HSCT for Primary Immunodeficiency (PID). We report 12 cases of 944 patients, who developed non-PTLD malignancy post-HSCT for PID.
中文翻译：
原发性免疫缺陷患者 HSCT 后的非 PTLD 恶性肿瘤：英国经验
恶性疾病的造血干细胞移植 (HSCT) 后继发性恶性肿瘤是公认的。很少有关于原发性免疫缺陷 (PID) 的 HSCT 后恶性肿瘤的已发表报告。我们报告了 12 例 944 例患者，他们在 PID 的 HSCT 后发展为非 PTLD 恶性肿瘤。
京公网安备 11010802027423号